Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

Description

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Conditions

Bipolar Disorder, Manic

Study Overview

Study Details

Study overview

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Lumateperone in the Acute Treatment of Patients With Manic Episodes or Manic Episodes With Mixed Features Associated With Bipolar I Disorder (Bipolar Mania)

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

Condition
Bipolar Disorder, Manic
Intervention / Treatment

-

Contacts and Locations

Rogers

Clinical Site, Rogers, Arkansas, United States, 72758

Bellflower

Clinical Site, Bellflower, California, United States, 90706

Culver City

Clinical Site, Culver City, California, United States, 90230

Garden Grove

Clinical Site, Garden Grove, California, United States, 92845

Lemon Grove

Clinical Site, Lemon Grove, California, United States, 91945

Montclair

Clinical Site, Montclair, California, United States, 91763

Hallandale Beach

Clinical Site, Hallandale Beach, Florida, United States, 33009

Hialeah

Clinical Site, Hialeah, Florida, United States, 33016

Miami Gardens

Clinical Site, Miami Gardens, Florida, United States, 33056

Miami Lakes

Clinical Site, Miami Lakes, Florida, United States, 33016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Able to provide written informed consent before the initiation of any study specific procedures;
  • 2. Male or female inpatient, between the ages of 18 and 75 years, inclusive;
  • 3. Meets the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM 5) criteria for bipolar I disorder with a current episode of mania or mania with mixed features with or without psychotic symptoms, as confirmed by a trained and Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT);
  • 4. YMRS total score ≥ 20 and a score of at least 4 on two of the following YMRS items: irritability, speech, content, and disruptive/aggressive behavior at Screening and Baseline;
  • 5. Hospitalized voluntarily before Screening or admitted to inpatient unit at Visit 1 with a primary diagnosis of mania but not \> 14 days before Screening. Hospital admission must be a result of the current manic episode.
  • 1. Has a current primary DSM 5 psychiatric diagnosis other than bipolar disorder. These include:
  • 1. Schizophrenia, schizoaffective disorder, or other psychotic disorders;
  • 2. Dementia or other cognitive disorders;
  • 3. Intellectual disability;
  • 4. Moderate or severe substance use disorder (excluding for nicotine);
  • 2. Experiencing first manic episode;
  • 3. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of his/her participation in the study or
  • 1. At Screening, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening; or
  • 2. At Screening, the patient has had 1 or more suicidal attempts within 2 years prior to Screening; or
  • 3. At Baseline, the patient scores "yes" on Items 4 or 5 in the Suicidal Ideation section of the C-SSRS since the Screening Visit; or
  • 4. At Screening or Baseline, scores ≥ 4 on Item 10 (suicidal thoughts) on the rater administered Montgomery-Åsberg Depression Rating Scale (MADRS); or
  • 5. Considered to be an imminent danger to himself/herself or others.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Intra-Cellular Therapies, Inc.,

Study Record Dates

2026-04